A Clinical Trial to Evaluate the Immunogenicity Bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell) in Healthy Population Aged 18-59 Years
Latest Information Update: 29 Apr 2024
At a glance
- Drugs Recombinant COVID-19 vaccine - WestVac Biopharma/West China Hospital Sichuan University (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Westvac Biopharma
Most Recent Events
- 23 Apr 2024 Status changed from not yet recruiting to completed.
- 22 Jul 2022 New trial record